Vertex Pharmaceuticals Reports Q3 Revenue Beat Amid Slight EPS Miss
Vertex Pharmaceuticals (VRTX) reported third-quarter results featuring a revenue beat of $3.44 billion, representing an 11.7% increase year-over-year. While the top-line performance exceeded expectations by $10 million, the company's Non-GAAP earnings per share (EPS) of $4.76 fell slightly short of estimates by $0.02. The company also updated its full-year 2026 financial guidance, projecting total revenue between $13.15 billion and $13.25 billion, which sits slightly below the previous consensus of $13.28 billion. Despite the slight miss in EPS and revised revenue outlook, shares responded positively with a 1.3% increase.
Tickers: $VRTX
Topics: earnings miss financial guidance quarterly results revenue beat